Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.66 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | F12 | P00748 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210918 | 0.92 | NPC1 (0.74) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL13162001 | 0.89 | NPC1 (0.55) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL13162889 | 0.88 | NPC1 (0.53) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL4066954 | 0.85 | TAS1R3 (0.88) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL15341542 | 0.85 | NPC1 (0.54) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL10282412 | 0.83 | RAB9A (0.86) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL10282411 | 0.83 | TAS1R3 (0.62) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL22720105 | 0.83 | TAS1R3 (0.62) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL455691 | 0.83 | RAB9A (0.53) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL3233932 | 0.83 | NPC1 (0.53) | TAS1R3TAS1R1TAS1R2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158864-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. | 2015-06-11 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TAS1R3 1218/4885TAS1R1 1469/4885TAS1R2 1346/4885 |
| US-20150158864-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | TAS1R3 882/4885TAS1R1 1374/4885TAS1R2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.